Tessa Therapeutics Announces $80 Million Financing Round

On December 20, 2017, Tessa Therapeutics, an international biopharmaceutical company focused on T-cell therapy for solid tumors, announced that it has completed an $80 million Series A round of financing led by Temasek. Wilson Sonsini Goodrich & Rosati represented Temasek on U.S. matters in the transaction.

According to a press release, the investment will be used to further advance Tessa's clinical pipeline and to bring new therapies, based on the company's Virus Specific T-cell (VST) platform, into clinical trials.

The WSGR team representing Temasek in the transaction was led by partners Barry Taylor, Michael Rabson, and Sriram Krishnamurthy, and associates Christopher W. McAndrew, Jon Nygaard, and Shira Oyserman.

For additional information, please see Tessa's press release.